Switzerland Archives

More News! 30 Jul 2018

We May Soon Diagnose Traumatic Brain Injury With a Single Drop of Blood

Swiss and Spanish researchers are developing a diagnostic test that measures the severity of mild traumatic brain injury that delivers results in ten minutes with a single drop of blood. CT scans are currently the only reliable method for diagnosing mild traumatic brain injury. However, the technology is not available in all hospitals, is expensive […]

July 30, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 29 Jun 2018

Update: Yet Another ADC Company Makes Bank, This Time in Series B

Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M), reaching a total of 40M CHF (€34.6M) for the round. Novo Holdings joins the Boehringer Ingelheim Venture Fund and the PPF Capital Partners Fund as a major shareholder of the Swiss biotech, which continues to develop its ADCs for improved […]

June 29, 2018 - 3 minutesmins - By Editorial Team

More News! 18 Jun 2018

Swiss Biotech Tackles Brain Artery Constriction Caused by Hemorrhage

Idorsia will start a Phase III trial to study the efficacy of its drug in treating the constriction of arteries in the brain caused by release of chemicals linked to a previous bleed in this area. The Swiss biotech Idorsia will test the efficacy of its drug, clazosentan, for treating patients whose brain arteries have […]

June 18, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 15 May 2018

Swiss Company Raises Ambitious IPO to Fight Antibiotic Resistance

Polyphor has closed an IPO of CHF 165M (€138M) to continue developing a new class of antibiotics against pneumonia, as well as treatments for cystic fibrosis and breast cancer. Polyphor, based in Switzerland, has raised a substantial IPO of CHF 165M (€138M) on the SIX Swiss Exchange, surpassing its initial goal of CHF150M (€127M). The funds will […]

May 15, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 9 May 2018

Swiss Spin-off Secures Funding for Antibodies to Reach Difficult Targets

Memo Therapeutics has raised CHF 5M (€4,2M) to develop its antibody detection technology, which uses whole antibodies to reach difficult targets. Memo Therapeutics, a spin-off from ETH Zurich, has closed a Series A2 round of CHF 5M (€4,2M). The funding was provided by Redalpine Venture Partners and Zurich Cantonal Bank among other investors and will […]

May 9, 2018 - 1 minutemin - By Alexander Burik

News and Trends 24 Apr 2018

New Class of Antibiotics Combats the Three Deadliest Bacteria in the World

A new class of antibiotics developed by Polyphor has been shown to be effective against the three most dangerous drug-resistant bacteria in the world. Polyphor’s novel class of antibiotics has been shown to effectively combat the three bacteria marked as critical, priority 1 by the World Health Organization. To date, there are very limited to no […]

April 24, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 20 Apr 2018

Gene Therapy For Beta-Thalassemia Could Eliminate Need for Transfusions

Bluebird bio has obtained results from two clinical studies showing its new gene therapy could eliminate the need for red blood cell transfusions in patients with beta-thalassemia. The company plans to file for an EU approval of its treatment later this year. US firm bluebird bio has results from two clinical studies showing its LentiGlobin gene […]

April 20, 2018 - 2 minutesmins - By Alexander Burik

lundbeck prexton therapeutics acquisition parkinsons

News and Trends 16 Mar 2018

Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

Lundbeck is acquiring Prexton Therapeutics in a deal that could reach up to €905M if the Swiss company’s Parkinson’s treatment proves successful. Danish pharma Lundbeck has decided to boost its pipeline with the acquisition of Prexton Therapeutics. The deal grants Lundbeck with global rights to foliglurax, a drug to reduce the “off” time periods when Parkinson’s motor […]

March 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Mar 2018

Swiss VC Closes €86M Fund for Medical Biotech in Europe

BioMedPartners has raised CHF100M (€86M) that will be invested in medical biotech companies in Switzerland, Germany, and other EU countries. Swiss VC BioMedPartners has managed to gather some big European investors to close its third venture capital fund, called BioMedInvest III and sized at CHF 100M (€86M). Among the investors are the European Investment Fund […]

March 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

santhera multiple sclerosis trial idebenone

News and Trends 5 Mar 2018

Swiss Company Hits Another Slump with a Failed Multiple Sclerosis Trial

Just months after the EMA rejected its therapy for Duchenne muscular dystrophy, Swiss company Santhera reports negative data for its multiple sclerosis drug. Santhera Pharmaceuticals has reported this morning that a first clinical trial in patients with primary progressive multiple sclerosis (PPMS) failed to prove the company’s drug to have any effect on the progression of […]

March 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Idorsia Actelion Spin Off Jean Paul Clozel CEO

News and Trends 1 Mar 2018

How is Actelion Spin-Off Idorsia Doing One Year Later?

Actelion’s spin-off Idorsia was blessed with a large pipeline and a healthy bank balance. How has the biotech’s first year of business gone? Just over a year ago, Actelion, the largest biotech in Europe at the time, was snapped up by Johnson & Johnson for a massive €27.9Bn. “This deal is unique: J&J gets its […]

March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

multiple sclerosis antibody CIDP geneuro 1

News and Trends 26 Feb 2018

This Multiple Sclerosis Drug Could Help to Fight Another Autoimmune Disease

The FDA has awarded Orphan Drug Designation to GeNeuro’s antibody for the treatment of a rare autoimmune disease following promising Phase IIb results in multiple sclerosis patients. GeNeuro develops therapies targeting factors encoded by human endogenous retroviruses that are implicated in neurological and autoimmune disorders. The biotech’s drug, GNbAC1, which is being developed for multiple […]

February 26, 2018 - 2 minutesmins - By Alex Dale

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us